• Consensus Rating: Buy
  • Consensus Price Target: $46.20
  • Forecasted Upside: 273.79 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$12.36
▼ -0.43 (-3.36%)

This chart shows the closing price for CDNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CareDx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDNA

Analyst Price Target is $46.20
▲ +273.79% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CareDx in the last 3 months. The average price target is $46.20, with a high forecast of $87.00 and a low forecast of $26.00. The average price target represents a 273.79% upside from the last price of $12.36.

This chart shows the closing price for CDNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in CareDx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2021
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2022
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/7/2022Raymond JamesLower TargetStrong-Buy$35.00 ➝ $26.00Low
11/7/2022BTIG ResearchLower TargetBuy$37.00 ➝ $28.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$45.00 ➝ $40.00Low
8/15/2022BTIG ResearchLower Target$37.00Low
4/25/2022StephensInitiated CoverageOverweight$50.00High
2/28/2022BTIG ResearchLower Target$100.00 ➝ $65.00High
2/25/2022Craig HallumLower Target$106.00 ➝ $87.00Low
2/25/2022Raymond JamesLower TargetStrong-Buy$90.00 ➝ $52.00Medium
10/29/2021BTIG ResearchReiterated RatingBuy$99.00Low
10/29/2021Raymond JamesLower TargetStrong-Buy$108.00 ➝ $90.00High
7/30/2021Piper SandlerBoost TargetOverweight$100.00 ➝ $110.00High
7/20/2021BTIG ResearchInitiated CoverageBuy$115.00Low
6/28/2021Raymond JamesBoost TargetStrong-Buy$90.00 ➝ $108.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$95.00Low
5/6/2021Raymond JamesLower TargetStrong-Buy$98.00 ➝ $90.00High
5/6/2021Piper SandlerBoost TargetOverweight$93.00 ➝ $100.00High
3/3/2021Raymond JamesLower TargetStrong-Buy$101.00 ➝ $98.00High
2/26/2021HC WainwrightDowngradeBuy ➝ NeutralLow
2/25/2021Raymond JamesReiterated RatingStrong-Buy$98.00Low
1/12/2021Piper SandlerBoost TargetOverweight$62.00 ➝ $93.00Medium
1/4/2021Craig HallumBoost TargetBuy$66.00 ➝ $94.00N/A
12/17/2020BTIG ResearchBoost TargetBuy$55.00 ➝ $80.00High
12/10/2020Raymond JamesBoost TargetStrong-Buy$62.00 ➝ $75.00High
10/30/2020Raymond JamesBoost TargetStrong-Buy$42.00 ➝ $62.00High
10/30/2020HC WainwrightBoost TargetBuy$47.00 ➝ $55.00High
10/8/2020BTIG ResearchBoost TargetBuy$45.00 ➝ $55.00High
10/8/2020Craig HallumBoost TargetBuy$46.00 ➝ $66.00High
10/8/2020HC WainwrightBoost TargetBuy$45.00 ➝ $47.00High
10/8/2020Piper SandlerBoost TargetOverweight$54.00 ➝ $62.00High
10/2/2020HC WainwrightBoost TargetBuy$40.00 ➝ $45.00Low
8/10/2020Jefferies Financial GroupReiterated RatingBuy$35.00High
8/6/2020BTIG ResearchBoost TargetBuy$40.00 ➝ $45.00Medium
8/5/2020Raymond JamesBoost TargetStrong-Buy$40.00 ➝ $42.00High
8/5/2020HC WainwrightBoost TargetBuy$37.00 ➝ $40.00High
6/29/2020Piper SandlerReiterated RatingBuy$54.00High
6/26/2020BTIG ResearchInitiated CoverageBuy$40.00High
6/19/2020Raymond JamesReiterated RatingBuy$40.00High
6/19/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $37.00High
5/18/2020HC WainwrightReiterated RatingBuy$40.00High
5/1/2020HC WainwrightLower TargetBuy$43.00 ➝ $40.00High
5/1/2020Piper SandlerLower TargetOverweight$59.00 ➝ $54.00High
4/24/2020HC WainwrightReiterated RatingBuy$43.00High
4/9/2020Craig HallumLower TargetBuy$48.00 ➝ $42.00Medium
3/23/2020HC WainwrightReiterated RatingBuyHigh
1/27/2020Piper SandlerReiterated RatingBuy$63.00High
1/21/2020HC WainwrightReiterated RatingBuy$43.00High
11/1/2019Piper Jaffray CompaniesSet TargetBuy$63.00N/A
10/1/2019Craig HallumInitiated CoverageBuy$48.00Low
8/23/2019HC WainwrightSet TargetBuy$43.00Low
8/22/2019Piper Jaffray CompaniesSet TargetBuy$63.00Low
8/2/2019HC WainwrightReiterated RatingBuyLow
8/2/2019Raymond JamesBoost TargetStrong-Buy$46.00 ➝ $48.00High
8/2/2019Piper Jaffray CompaniesBoost TargetOverweight$50.00 ➝ $63.00Medium
7/11/2019Craig HallumSet TargetBuy ➝ Positive$40.00 ➝ $48.00Low
5/9/2019HC WainwrightUpgradeNeutral ➝ Buy$30.00 ➝ $43.00Low
5/9/2019Piper Jaffray CompaniesBoost TargetOverweight$42.00 ➝ $50.00High
3/22/2019Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$38.00 ➝ $46.00High
3/7/2019HC WainwrightSet TargetHold$30.00Medium
2/15/2019Jefferies Financial GroupInitiated CoverageBuy$35.00High
2/4/2019HC WainwrightReiterated RatingHold$27.00Medium
12/21/2018HC WainwrightReiterated RatingHold$27.00High
11/12/2018HC WainwrightSet TargetHold$28.00High
11/9/2018Craig HallumReiterated RatingBuy$40.00High
10/23/2018Raymond JamesReiterated RatingStrong-Buy ➝ Strong-Buy$30.00Medium
10/3/2018Craig HallumSet TargetBuy$20.00 ➝ $35.00High
9/18/2018HC WainwrightReiterated RatingNeutral ➝ Neutral$22.00High
9/5/2018Piper Jaffray CompaniesBoost Target$42.00Low
8/10/2018HC WainwrightSet TargetHold$17.00High
6/28/2018HC WainwrightReiterated RatingHold$15.00Medium
6/19/2018HC WainwrightDowngradeBuy ➝ Neutral$15.00Medium
6/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$17.00High
5/11/2018HC WainwrightReiterated RatingBuy$14.00Medium
4/12/2018HC WainwrightSet TargetBuy$12.00High
4/2/2018HC WainwrightSet TargetBuy$12.00Low
3/23/2018HC WainwrightSet TargetBuy$12.00High
1/31/2018HC WainwrightReiterated RatingBuy$12.00Medium
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 10 very positive mentions
  • 25 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
6/1/2022
  • 9 very positive mentions
  • 28 positive mentions
  • 12 negative mentions
  • 4 very negative mentions
7/1/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
7/31/2022
  • 9 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
8/30/2022
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
9/29/2022
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $12.36
Low: $12.03
High: $12.97

50 Day Range

MA: $16.42
Low: $12.42
High: $20.05

52 Week Range

Now: $12.36
Low: $11.92
High: $47.82

Volume

63,131 shs

Average Volume

835,844 shs

Market Capitalization

$661.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of CareDx?

The following Wall Street analysts have issued stock ratings on CareDx in the last year: BTIG Research, Craig Hallum, Raymond James, Stephens, StockNews.com, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for CDNA.

What is the current price target for CareDx?

5 Wall Street analysts have set twelve-month price targets for CareDx in the last year. Their average twelve-month price target is $46.20, suggesting a possible upside of 261.2%. Craig Hallum has the highest price target set, predicting CDNA will reach $87.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $26.00 for CareDx in the next year.
View the latest price targets for CDNA.

What is the current consensus analyst rating for CareDx?

CareDx currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDNA will outperform the market and that investors should add to their positions of CareDx.
View the latest ratings for CDNA.

What other companies compete with CareDx?

How do I contact CareDx's investor relations team?

CareDx's physical mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (415) 287-2300 and its investor relations email address is [email protected] The official website for CareDx is www.caredxinc.com. Learn More about contacing CareDx investor relations.